2020/5/27 11:20:14
With the advantages of high sensitivity and accuracy, easy portability, simple operation, low detection time, no environmental requirements and low cost, POCT using molecular diagnostic methods is likely to become the mainstream of the future development of the in vitro diagnostic industry. After the outbreak of the new crown epidemic, the lack of PCR laboratory conditions at the grassroots level could not quickly achieve on-site testing, and exposed the shortcomings of nucleic acid testing.
However, the technical threshold of the POCT molecular diagnostic system is very high, and it is basically monopolized by several giants such as Danaher, Roche, Biomerieux, and Abbott. Many domestic companies have tried to copy these products without success. In 2013, BioMerieux acquired Filmarray for US $ 450 million, Danaher acquired Cepheid for US $ 4 billion in 2016, and Wanfu Bio, a leading domestic POCT company, invested POCT molecular diagnostic company Atlas Genetics for RMB 125 million. It fully shows the scarcity of POCT molecular diagnostic platform technology. However, domestic related technologies are also rising, and many products have also played an important role in the epidemic.
(From admin)